BBBporter™ Technology Platform

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

RMT-Targeting Biologics Development Services

Inquiry

Biologics are a promising class of medicines for the disorders of the central nervous system (CNS). However, their effectiveness is hindered by the blood-brain barrier (BBB), which significantly limits their ability to enter the brain when administered intravenously. One innovative approach to overcome this challenge involves targeting endogenous receptor-mediated transcytosis (RMT) systems. These systems use vesicular trafficking to transport ligands across the BBB endothelium. The general strategy for delivering biologics into the brain via RMT is to conjugate a receptor-targeting moiety to the desired therapeutic cargos. Studies have shown that proteins, genes, and drug-loaded particles can all be delivered via RMT.

Diagram illustrating the mechanisms of RMT and AMT across the blood-brain barrier. — Fig. 1 Schematic representation of the receptor-mediated transcytosis (RMT) and adsorptive-mediated transcytosis (AMT) processes in the brain. (Gao, *et al*., 2021)

Our Services

At Ace Therapeutics, we provide comprehensive RMT-targeting biologic development services to help clients design BBB delivery vector-drug conjugates for optimal brain-targeted drug delivery. Our expertise spans antibody engineering, conjugate optimization, nanoparticle formulation, and preclinical validation to accelerate the development of RMT-based drug delivery systems.

Our Strategies for Formulating RMT-Targeting Biologics

Ace Therapeutics offers several strategies for linking therapeutic cargoes, such as peptides, proteins, antibodies, and nanoparticles loaded with nucleic acids, with BBB delivery vectors.

Methods	Services
Direct Conjugation	We can couple the biologic to the RMT targeting moiety using the following methods: Fusion Proteins Fusion of RMT ligands (e.g., anti-TfR antibody, insulin, and IGF1) with therapeutic cargos (e.g., enzymes, neurotrophic factors, and antibodies) to produce single-chain fusion proteins. Various linker options (rigid or flexible, enzyme-cleavable) to maintain the proper folding and activity of each domain. Optimized expression systems (e.g., HEK293, CHO) to support high-yield and high-purity protein production. Chemical Linkage Site-specific or non-specific conjugation of RMT ligands to biologics using chemical linkage (e.g., streptavidin/biotin linkage).
Nanoparticle-Based Encapsulation	We can design the formulation of nanoparticles decorated with RMT targeting ligands, and loaded with the biologics of interest. Various delivery vehicles (e.g., liposomes, polymeric nanoparticles, solid lipid nanoparticles). Surface functionalization with RMT ligands (e.g., TfR-binding peptides).

Methods

Services

Direct Conjugation

We can couple the biologic to the RMT targeting moiety using the following methods:
Fusion Proteins

Fusion of RMT ligands (e.g., anti-TfR antibody, insulin, and IGF1) with therapeutic cargos (e.g., enzymes, neurotrophic factors, and antibodies) to produce single-chain fusion proteins.
Various linker options (rigid or flexible, enzyme-cleavable) to maintain the proper folding and activity of each domain.
Optimized expression systems (e.g., HEK293, CHO) to support high-yield and high-purity protein production.

Chemical Linkage

Site-specific or non-specific conjugation of RMT ligands to biologics using chemical linkage (e.g., streptavidin/biotin linkage).

Nanoparticle-Based Encapsulation

We can design the formulation of nanoparticles decorated with RMT targeting ligands, and loaded with the biologics of interest.

Various delivery vehicles (e.g., liposomes, polymeric nanoparticles, solid lipid nanoparticles).
Surface functionalization with RMT ligands (e.g., TfR-binding peptides).

Advantages of Our Services

Efficient non-invasive delivery: Our services enable efficient, non-invasive drug delivery for your therapeutic candidates.
Versatile targeting solutions: Our RMT-targeted biologic development services are applicable to monoclonal antibodies (mAbs), recombinant enzymes, gene therapies, and more.
Customizable design: Our RMT-targeting ligands and RMT-based brain drug delivery strategies can be customized to specific CNS targets and indications.
End-to-end development: We provide one-stop services ranging from RMT receptor selection to preclinical evaluation.

With extensive expertise in BBB biology, CNS pharmacology, and biologics development, Ace Therapeutics is your ideal partner for developing RMT-targeted biologics for brain delivery. Whether you're advancing early discovery or progressing toward clinical translation, we offer science-driven solutions tailored to your goals. Contact us today to learn more about our RMT-based brain drug delivery services.

Reference

Gao, Y., et al. (2021). Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: A review. Drug Delivery and Translational Research, 11(5), 1818-1828.